
PRAHEALTHSCIENCES
REAL WORLD SOLUTIONS

REAL WORLD RESEARCH

We combine real world evidence and real world research for real results. As the life sciences market continues to evolve, companies must provide evidence and demonstrate the value of products to multiple stakeholders. Real World Evidence (RWE) and gaining market access are inherent to reach this goal and increasingly crucial to ensure patient access and commercial success. Access to and the proper use and interpretation of so much real-world data – from across the entire healthcare system – is now critical to product development. From biotechs to big pharma, PRA has the flexibility, scalability and expertise you needed for real world research.

EXPERIENCE

LIFE SCIENCE LEADER PHASE IV AWARD (OVERALL AND BIG PHARMA)

CUMULATIVE Nº. OF YEARS IN REAL WORLD SOLUTIONS

445+

Nº. OF REAL WORLD STUDIES

330+

265, 600 PATIENTS

18, 800+ SITES

60+ COUNTRIES

Nº. OF POST-SECONDARY DEGREES

245+

Nº. OF LANGUAGES SPOKEN

BONJOUR

你好

OVER 17

WE UNDERSTAND WHAT POST-MARKETING RESEARCH IS – AND JUST AS IMPORTANTLY – WHAT IT IS NOT. OUR INSIGHT IS WHAT SETS US APART.

REAL WORLD EXPERTISE

PRA's multidisciplinary team of experts develop flexible strategies that help advance safer drugs to market, while meeting our stakeholders' diverse needs. Clients also realize a significant value when working with PRA Real World Solutions. Our industry-leading project teams and experts deliver the highest efficiency and value by integrating scientific rigor with solid operational processes and data-driven approaches.



REAL LIFE STUDIES

We innovate ways to capture, analyze, and qualify product performance — and patient experience — in the real world, utilizing our patient-focused mobile platform, Clinical6. PRA focuses on ways to tailor study participation to the patient, rather than the other way around. By bringing research to the patient, we don't just make studies better, we make them better for the patient.

REAL WORLD INNOVATION

Our Non-Interventional Country Information (NICI) system provides current observational research regulatory requirements for 60 countries, reducing activation timelines. In addition, we use an array of state-of-the-art analytical tools to conduct data review and trend identification, evaluating each site's training needs, and supporting the collection of timely and high-quality data.

eCONSENTS

Complies with regulatory guidance; fully validated and supported by central monitoring

Reduces study timelines, simplifies enrollment, and supports virtual studies

SECONDARY DATA

Generates comprehensive evidence when combined with primary data

Shapes feasibility and study design while driving efficiency and cost containment

SOCIAL LISTENING

Captures real-time conversations and attitudes of patients and investigators

Translates into targeted, engaging patient awareness and retention strategies

WEARABLE TECHNOLOGY

Engages patients as true partners in research while reducing site burden

Facilitates real world data collection in real time

ELECTRONIC PATIENT-REPORTED OUTCOMES

Provides local language capabilities and encourages participation and motivation

Yields high quality patient data and reduces costs through our mobile app platform

"Our Global Study Coordinating Hubs are comprised of multilingual site management associates covering more than 60 countries to help guide the strategy and execution of high-quality, late-phase programs that evaluate the safety and effectiveness of treatments in the real-world and lead to safer, more accessible drugs."

MARIA HARRISON,
VP, Real World Solutions



Product development is really complicated, but the reason we do it is really simple. People aren't simply patients — people are people.

Patient treatment is complex, but so are patients' lives. We meet patients where they are in the real world and we find the meaningful data to answer the ultimate questions: "Does this work? Is it effective?"

We also understand that the work doesn't end once a product leaves the controlled clinical setting. We want to know if the product is safe, well-tolerated, and even preferred by patients and/or their caregivers.

PRA Health Sciences conducts comprehensive Phase I-IV biopharmaceutical product development.
To learn more about our solutions, please visit us at prahs.com or email us at prahealthsciences@prahs.com.

SEPT2018